YolTech Therapeutics Secures $45 Million in Series B Funding to Advance Gene-Editing Therapies YolTech Therapeutics has successfully raised $45 million in Series B funding, led by AstraZeneca-CICC, to progress its innovative gene-editing therapies.

YolTech Therapeutics Secures $45 Million in Series B Funding to Advance Gene-Editing Therapies #China #Shanghai #YolTech_Therapeutics #gene-editing #AstraZeneca-CICC

YolTech Therapeutics Unveils Promising Results for YOLT-203, Targeting Primary Hyperoxaluria Type 1 YolTech Therapeutics shares encouraging data on YOLT-203, an innovative gene-editing treatment for Primary Hyperoxaluria Type 1, showcasing safety and efficacy.

YolTech Therapeutics Unveils Promising Results for YOLT-203, Targeting Primary Hyperoxaluria Type 1 #China #Shanghai #YOLT-203 #YolTech_Therapeutics #PH1

YolTech Therapeutics Launches Exciting Gene Editing Clinical Trial for β-Thalassemia YolTech Therapeutics embarks on a significant clinical trial for YOLT-204, an innovative gene therapy targeting β-thalassemia, aiming for curative outcomes.

YolTech Therapeutics Launches Exciting Gene Editing Clinical Trial for β-Thalassemia #China #Shanghai #YolTech_Therapeutics #YOLT-204 #β-Thalassemia